Dedicated to developing new human pluripotent stem cell
(hPSC) based cell therapy products

UniXell is an innovative biotechnology company specialized in developing hPSC based cell therapy products.

Since its founding in 2021, Unixell has developed multiple key technology platforms, including Reprogramming technology, Stem cell differentiation, SISBAR pedigree tracing technology and High-precision gene editing. With these best-in-class technology platforms and an excellent scientific team, Unixell focuses on unmet medical needs, including neurodegenerative diseases and rare diseases.

  • 5


  • 70%

    High proportion of PhD in leadership team

  • 4000

    GMP Facility and office areas